Explore /
Poster
/ A phase 1/2 multicenter investigator-initiated trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

A phase 1/2 multicenter investigator-initiated trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

Authors

David R Wise

Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York, NY

David R Wise , Russell Kent Pachynski , Samuel R. Denmeade , Rahul Raj Aggarwal , Victor Ricardo Adorno Febles , Arjun Vasant Balar , Minas P. Economides , Cynthia A. Sirard , Andrea Troxel , Sarah Griglun , Dayna Leis , Nina Yang , Viktoriya Aranchiy , Sabrina Machado , Erika Waalkes , Gabrielle Gargano , Fang-Ming Deng , Ezeddin Fadel , Luis Chiriboga , Jonathan Melamed

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer– Advanced/Castrate-Resistant

Clinical Trial Registration Number

NCT03837353

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 5048)

DOI

10.1200/JCO.2022.40.16_suppl.5048

Abstract #

5048

Poster Bd #

232

Abstract Disclosures

Similar Posters

Poster

2019 Genitourinary Cancers Symposium

$Phase I/II dose-escalation trial of fractionated dose <sup>177</sup>Lu-J591 plus <sup>177</sup>Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC).$